EvanHallMDMPhil

Oncology • Seattle, WA

Genitourinary Oncology, Melanoma

Assistant Professor, University of Washington, Division of Medical Oncology Physician, Seattle Cancer Care Alliance

Join to view full profile

Dr. Hall is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hall's full profile

Already have an account?

Office
825 Eastlake Ave E
Seattle, WA 98109
Phone+1 206-606-7222

Education & Training

Stanford Health CareFellowship, Hematology and Medical Oncology, 2016 - 2019
Stanford Health Care-Sponsored Stanford UniversityChief Residency, Internal Medicine, 2015 - 2016
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2012 - 2015
University of California San Diego School of MedicineClass of 2012
University of CambridgeM.Phil., Biological Sciences, 2007 - 2008
Pomona CollegeBA, Chemistry, 2003 - 2007

Certifications & Licensure

AK State Medical License 2022 - 2026
MT State Medical License 2022 - 2026
ID State Medical License 2022 - 2025
WA State Medical License 2019 - 2025
CA State Medical License 2013 - 2020
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Adjuvant Proton Beam Radiation Therapy for Sinonasal Mucosal Melanoma.
Jamie S K Takayesu, Upendra Parvathaneni, George E Laramore, Neil Panjwani, Jennifer Sillings
Cancer Reports. 2025-02-01
Dual-energy CT iodine concentration as a biomarker for immunotherapy treatment response in metastatic melanoma and renal cell carcinoma patients.
Natalie Wiley, Mladen Zecevic, Vivian Ho, Matthew J Stolzberg, Danielle Cox
European Radiology. 2025-01-28
Metastatic SMARCB1-Deficient Renal Medullary Carcinoma without Hemoglobinopathy with Durable and Dramatic Response to Pembrolizumab plus Lenvatinib: Case Report.
William McCamy, Maryam Yousefiasl, Maria Tretiakova, Minal Jagtiani, Evan Hall
Case Reports in Oncology. 2024-09-17

Lectures

Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic cancer center.
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019

Press Mentions

‘Cure’ in Cancer: Should Oncologists Use the Word?February 4th, 2025
6 Steps to Take After a Kidney Cancer DiagnosisJune 11th, 2023